

IN THE CLAIMS:

Claim 1 (**previously presented**): A non-interacting drug combination comprising a first drug, which is the HMG-CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, and a second drug, which is an inhibitor, inducer or substrate of P450 isoenzyme 3A4.

Claim 2 (**original**): A non-interacting drug combination, as claimed in claim 1, wherein the second drug is an inhibitor or inducer of P450 isoenzyme 3A4.

Claim 3 (**cancelled**).

Claim 4 (**previously presented**): A non-interacting drug combination, as claimed in claim 1, wherein the second drug is a cholesterol lowering drug and is an inducer, inhibitor or substrate of P450 isoenzyme 3A4.

Claim 5 (**previously presented**): A non-interacting drug combination, as claimed in claim 4, wherein the second drug is selected from bezafibrate, clofibrate, ciprofibrate, fenofibrate and niacin.

Claim 6 (**original**): A non-interacting drug combination, as claimed in claim 5, wherein the second drug is fenofibrate.

Claim 7 (**withdrawn**): A non-interacting drug combination, as claimed in claim 1, wherein the second drug is used in treating cardiovascular conditions and is also an inhibitor, inducer or substrate of P450 isoenzyme 3A4.

Claim 8 (**withdrawn**): A non-interacting drug combination, as claimed in claim 7, wherein the second drug is selected from digitoxin, diltiazem, losartan, nifedipine, quinidine, verapamil and warfarin.

Claim 9 (**withdrawn**): A non-interacting drug combination, as claimed in claim 1, wherein the second drug is used in immunosuppression therapy and is an inducer, inhibitor or substrate of P450 isoenzyme 3A4.

Claim 10 (**withdrawn**): A non-interacting drug combination, as claimed in claim 9, wherein the second drug is selected from cyclosporin, tacrolimus and a corticosteroid.

Claim 11 (**cancelled**).

Claim 12 (**previously presented**): A pharmaceutical formulation comprising the non-interacting drug combination of claim 1 together with a pharmaceutically-acceptable diluent, carrier or adjuvant.

Claim 13 (**withdrawn**): A pharmaceutical formulation, as claimed in claim 12, wherein the second drug is a substrate of P450 isoenzyme 3A4 and is selected from acetaminophen, aldrin, aflentanil, amiodorane, astemizole, benzphetamine, budenoside, carbamazepine, cyclophosphamide, cyclosporin, dapsone, digitoxin, diltiazem, diazepam, erythromycin, etoposide, flutamide, hydroxyarginine, ifosfamide, imipramine, lansoprazole, lidocaine, lovastatin, losartan, lovastatin, midazolam, nifedipine, omeprazole, quinidine, rapamycin, retenoic acid, steroids, tacrolimus, teniposide, theophylline, toremifene, triazolam, troleandomycin, verapamil, warfarin, zatosetron and zonisamide.

Claim 14 (**withdrawn**): A pharmaceutical formulation, as claimed in claim 12, wherein the second drug is an inhibitor of P450 isoenzyme 3A4 and is selected from clotrimazole, ethinylestradiol, gestodene, itraconazole, ketoconazole, miconazole, diltiazem, naringenin, erythromycin, cyclosporin and triacetyloleandomycin.

Claim 15 (**withdrawn**): A pharmaceutical formulation, as claimed in claim 12, wherein the second drug is an inducer of P450 isoenzyme 3A4 is selected carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, sulfadimidine, sulfinipyrazone and triacetyloleandomycin.

Claims 16-32 (**cancelled**).

Claim 33 (**withdrawn**): A pharmacy pack comprising the non-interacting drug combination of claim 1, comprising said first drug and said second drug as separate dosage forms.

Claim 34 (**withdrawn**): A method for the treatment of hypercholesterolaemia or mixed hyperlipidaemia in a patient in need thereof, said method comprising administering to said patient an effective amount of the pharmaceutical formulation of claim 12.

Claim 35 (**withdrawn**): A method for the treatment of hypercholesterolaemia or mixed hyperlipidaemia in a patient in need thereof, said method comprising administering to said patient an effective amount of said first drug and an effective amount of said second drug, as claimed in claim 1, as separate dosage forms.

Claim 36 (**withdrawn**): The method of claim 35 where said first and second drugs are administered simultaneously.

Claim 37 (**withdrawn**): The method of claim 35 wherein said first and second drugs are administered sequentially.

Claim 38 (**withdrawn**): The method of any one of claims 34 to 37 wherein said first drug is dosed at 5, 10, 20, 40 or 80 mg once per day.